Literature DB >> 20944564

Geron trial resumes, but standards for stem cell trials remain elusive.

Stephen Strauss.   

Abstract

Mesh：

Year:  2010        PMID： 20944564     DOI： 10.1038/nbt1010-989

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Cochrane meta-analysis on alpha-1 antitrypsin prompts furor.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

2.  Up for grabs.

Authors:  Michael Eisenstein
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

3.  Pharma's developing interest in stem cells.

Authors:  Ruth McKernan; John McNeish; Devyn Smith
Journal:  Cell Stem Cell       Date:  2010-06-04       Impact factor: 24.633
  3 in total
  28 in total

1.  Embryonic stem cell pioneer Geron exits field, cuts losses.

Authors:  Simon Frantz
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  Regulation of stem cell-based therapies in Canada: current issues and concerns.

Authors:  Barbara von Tigerstrom; Thu Minh Nguyen; Bartha Maria Knoppers
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 3.  Technical approaches to induce selective cell death of pluripotent stem cells.

Authors:  Ho-Chang Jeong; Seung-Ju Cho; Mi-Ok Lee; Hyuk-Jin Cha
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

Review 4.  Stem cell therapy: an exercise in patience and prudence.

Authors:  Huan-Ting Lin; Makoto Otsu; Hiromitsu Nakauchi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-05       Impact factor: 6.237

Review 5.  Concise review: cell therapies: the route to widespread adoption.

Authors:  Lucy Foley; Michael Whitaker
Journal:  Stem Cells Transl Med       Date:  2012-05-09       Impact factor: 6.940

6.  Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice.

Authors:  Satoshi Nori; Yohei Okada; Akimasa Yasuda; Osahiko Tsuji; Yuichiro Takahashi; Yoshiomi Kobayashi; Kanehiro Fujiyoshi; Masato Koike; Yasuo Uchiyama; Eiji Ikeda; Yoshiaki Toyama; Shinya Yamanaka; Masaya Nakamura; Hideyuki Okano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

Review 7.  Tracking gene and cell fate for therapeutic gain.

Authors:  Nigel G Kooreman; Julia D Ransohoff; Joseph C Wu
Journal:  Nat Mater       Date:  2014-02       Impact factor: 43.841

Review 8.  The decision on the "optimal" human pluripotent stem cell.

Authors:  Margit Rosner; Katharina Schipany; Markus Hengstschläger
Journal:  Stem Cells Transl Med       Date:  2014-04-01       Impact factor: 6.940

Review 9.  From bench to FDA to bedside: US regulatory trends for new stem cell therapies.

Authors:  Paul S Knoepfler
Journal:  Adv Drug Deliv Rev       Date:  2014-12-07       Impact factor: 15.470

Review 10.  Pluripotent stem cells and gene therapy.

Authors:  Pavel Simara; Jason A Motl; Dan S Kaufman
Journal:  Transl Res       Date:  2013-01-23       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.